Table 2.
The 1-year combinations of classes of medication prescribed to the 8798 patients on PRT
| Maintenance treatment prescribed | PRT with high OCS exposure (n = 186) | PRT | ||
|---|---|---|---|---|
| n | % | n | % | |
| ICS + LABA | 61 | 32.8 | 3113 | 35.4 |
| ICS + LABA + LAMA | 46 | 24.7 | 1008 | 11.5 |
| ICS + LTRA + LABA + LAMA | 21 | 11.3 | 355 | 4.0 |
| ICS + LABA + LTRA | 15 | 8.1 | 1204 | 13.7 |
| LABA + LAMA | 13 | 7.0 | 635 | 7.2 |
| ICS monotherapy | 8 | 4.3 | 310 | 3.5 |
| LTRA monotherapy | 6 | 3.2 | 916 | 10.4 |
| LABA monotherapy | 5 | 2.7 | 340 | 3.9 |
| ICS + LAMA | 3 | 1.6 | 143 | 1.6 |
| LAMA monotherapy | 3 | 1.6 | 476 | 5.4 |
| ICS + LTRA | 2 | 1.1 | 126 | 1.4 |
| LTRA + LABA | 1 | 0.5 | 50 | 0.6 |
| LTRA + LAMA | 1 | 0.5 | 41 | 0.5 |
| ICS + LTRA + LAMA | 1 | 0.5 | 22 | 0.3 |
| LTRA + LABA + LAMA | 0 | 0.0 | 59 | 0.7 |
PRT persistent respiratory treatment, SABA short-acting beta2 agonist, OCS oral corticosteroids, ICS inhaled corticosteroids, LABA long-acting beta2 agonists, LTRA leukotriene receptors antagonists, LAMA long-acting muscarinic antagonist